Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

La Jolla Pharmaceutical’s shares surge after positive study results for hypotension treatment

Monday, February 27, 2017 7:11
% of readers think this story is Fact. Add your two cents.

Shares in La Jolla Pharmaceutical Company (NASDAQ:LJPC) surged 41% today ahead of the opening bell in the US after announcing positive top line results from the phase 3 study of its treatment for hypotension.

The ATHOS-3 study of the LJPC-501 drug, or angiotensin II, showed a highly statistically significant target blood pressure response, the primary efficacy endpoint, in patients with catecholamine resistant hypotension.

Hypotension is severely low blood pressure, which can lead to a life-threatening condition called shock.

The pharmaceutical company said the study revealed a trend towards longer survival with a 22% reduction in mortality risks.

An independent data safety monitoring board recommended the study continue as planned.

La Jolla plans to publish detailed results from ATHOS-3 later this year.

“These study results support that angiotensin II, a molecule first synthesised by Dr. Irvine Page at the Cleveland Clinic, improves outcomes in distributive shock patients requiring high-dose catecholamines,” said Daniel Sessler, chair of the Department of Outcomes Research at Cleveland Clinic.

“Given the high mortality from this condition, it is important to offer physicians another potential treatment option.”

Shares jumped 41.27% to $19.87 in pre-market trade. 

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.